Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Peer Review reports

Original Submission
31 Jul 2017	Submitted	Original manuscript
15 Aug 2017	Author responded	Author comments - Volkmar Mueller
Resubmission - Version 2
15 Aug 2017	Submitted	Manuscript version 2
27 Oct 2017	Reviewed	Reviewer Report - Bora Lim
27 Nov 2017	Reviewed	Reviewer Report - Moriwaki Toshikazu
9 Jan 2018	Author responded	Author comments - Volkmar Mueller
Resubmission - Version 3
9 Jan 2018	Submitted	Manuscript version 3
2 Feb 2018	Reviewed	Reviewer Report - Moriwaki Toshikazu
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
6 Mar 2018	Editorially accepted
15 Mar 2018	Article published	10.1186/s12885-018-4183-2

Back to article page